Search

Position of EHA on Personalized Medicine

 

The challenge
Despite its apparent complexity, personalized medicine could transform healthcare, by tailoring healthcare solutions to the individual patient, delivering ‘the right treatment to the right patient at the right time’ – and helping to get more value from healthcare spending.…

Read more

Faculty Information

We are honored that you have agreed to be a part of the faculty for the EHA-KCS Hematology Tutorial – Recent Advances in Lymphoid and Myeloid Malignancies, scheduled to be held on September 14-15, 2024 in Almaty, Kazakhstan.

Read more

Be part of the EHA community

How you can take an active role and help drive EHA's direction. As a membership organization, EHA is dependent on the dedication of its board and committee members.

Read more

Expert opinions for specific non-malignant hematologic diseases

Red Cells and Iron
Hemoglobinopathies: Sickle Cell Disease and Thalassemia

Sickle Cell Disease Association of America (SCDSS)
Sickle Cell Disease and COVID-19: An Outline to Decrease Burden and Minimize Morbidity 
Italian Society of Thalassemia and Hemoglobinopathies

Thalassemia and Hemoglobin disorders Italian Society
Thalassemia International Federation (TIF)
The COVID-19…

Read more

EHA Pediatric Hemato-Oncology Course programme

April 10, 202414:00–17:30: Red Cell and ConsultativeWelcome and presentation of the course.  Aims, expectations, and a brief look back. Presenters and topics
M. de Montalembert: Difficult management problems in sickle cell disease
M. D.

Read more

What an EHA Bilateral Collaborative Grant supports

Our EHA Bilateral Collaborative Grant supports basic and translational lab-based research in hematology. To reflect the collaborative spirit of the grant, the budget must be divided 50:50 between the two PIs.

Read more